市場調查報告書
商品編碼
736667

視神經脊髓炎相關疾病(NMOSD)- 流行病學預測 ∼2027年

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 60 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

主要7國(美國,英國,德國,法國,義大利,西班牙,日本)的視神經脊髓炎相關疾病(NMOSD)患病數在2016年估算為3萬2,382人。

本報告提供視神經脊髓炎相關疾病(NMOSD)市場相關調查,總括性彙整疾病概要,患者背景,主要7國患病數·診斷數的預測(今後10年份),診斷指南,市場規模,市場成長要素·障礙,競爭情形等調查。

目錄

第1章 重要的洞察

第2章 視神經脊髓炎相關疾病(NMOSD):市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 視神經脊髓炎相關疾病(NMOSD):疾病背景和概要

  • 簡介
  • 徵兆與症狀
  • 視神經脊髓炎/相關疾病(NMO/NMOSD)臨床症狀
  • 分類
  • 病因
  • 診斷
  • 診斷標準
  • 神經成像·神經生身體檢查

第4章 流行病學和患者人口

  • 主要的觀察

第5章 主要7國視神經脊髓炎相關疾病(NMOSD)的患病數

第6章 主要7國視神經脊髓炎相關疾病(NMOSD)的流行病學:各國

  • 美國
    • 前提和根據
    • 整體患病數
    • 患病數:性別
    • 整體診斷數
    • 診斷數:NMO-IgG
    • 臨床症狀
    • 不利事件
  • 主要歐洲5國
    • 德國
    • 法國
    • 義大利
    • 英國
    • 西班牙
  • 日本

第7章 市場成長要素

第8章 市場障礙

第9章 附錄

  • 調查方法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI0362

DelveInsight's 'Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Disease Understanding and Treatment Algorithm

The DelveInsight Neuromyelitis Optica Spectrum Disorder market report gives the thorough understanding of the Neuromyelitis Optica Spectrum Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis Optica Spectrum Disorder in the US, Europe, and Japan.

Neuromyelitis Optica Spectrum Disorder Epidemiology

The Neuromyelitis Optica Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female] and NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

According to DelveInsight, the prevalent cases of NMOSD was 32,382 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of NMOSD with 16,000 prevalent cases in 2016.

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female], NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

Report Scope

  • The report covers detailed overview of Neuromyelitis Optica Spectrum Disorder explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Neuromyelitis Optica Spectrum Disorder
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Neuromyelitis Optica Spectrum Disorder Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Neuromyelitis Optica Spectrum Disorder Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Neuromyelitis Optica Spectrum Disorder Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Neuromyelitis Optica Spectrum Disorder market
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder market.

Table of Contents

1. Key Insights

2. Neuromyelitis Optica Spectrum Disorder: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2017
  • 2.2. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2027

3. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Clinical features of NMO/NMOSD
  • 3.4. Classification
  • 3.5. Pathogenesis
  • 3.6. Diagnosis
  • 3.7. International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders
  • 3.8. Neuroimaging and neurophysiologic testing
    • 3.8.1. Considerations for AQP4-IgG serologic and another laboratory testing.
    • 3.8.2. Pediatric NMOSD criteria
    • 3.8.3. Monophasic NMOSD
    • 3.8.4. Systemic autoimmunity associated with NMOSD.
    • 3.8.5. Pathology
    • 3.8.6. Opticospinal MS

4. Epidemiology and Patient Population

  • 4.1. Key Findings

5. 7MM Total Prevalent Patient Population of NMO/NMOSD

6. Country Wise-Epidemiology of NMO/NMOSD

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of NMO/NMOSD
    • 6.1.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.1.4. Total Diagnosed Population of NMO/NMOSD
    • 6.1.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.1.6. Clinical Characterization of NMO/NMOSD
    • 6.1.7. Events of NMO/NMOSD
  • 6.2. EU5 Countries
    • 6.2.1. Assumptions and Rationale
  • 6.3. Germany
    • 6.3.1. Total Prevalent Population of NMO/NMOSD
    • 6.3.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.3.3. Total Diagnosed Population of NMO/NMOSD
    • 6.3.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.3.5. Clinical Characterization of NMO/NMOSD
    • 6.3.6. Events of NMO/NMOSD
  • 6.4. France
    • 6.4.1. Total Prevalent Population of NMO/NMOSD
    • 6.4.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.4.3. Total Diagnosed Population of NMO/NMOSD
    • 6.4.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.4.5. Clinical Characterization of NMO/NMOSD
    • 6.4.6. Events of NMO/NMOSD
  • 6.5. Italy
    • 6.5.1. Total Prevalent Population of NMO/NMOSD
    • 6.5.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.5.3. Total Diagnosed Population of NMO/NMOSD
    • 6.5.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.5.5. Clinical Characterization of NMO/NMOSD
    • 6.5.6. Events of NMO/NMOSD
  • 6.6. United Kingdom
    • 6.6.1. Total Prevalent Population of NMO/NMOSD
    • 6.6.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.6.3. Total Diagnosed Population of NMO/NMOSD
    • 6.6.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.6.5. Clinical Characterization of NMO/NMOSD
    • 6.6.6. Events of NMO/NMOSD
  • 6.7. Spain
    • 6.7.1. Total Prevalent Population of NMO/NMOSD
    • 6.7.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.7.3. Total Diagnosed Population of NMO/NMOSD
    • 6.7.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.7.5. Clinical Characterization of NMO/NMOSD
    • 6.7.6. Events of NMO/NMOSD
  • 6.8. Japan
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Total Prevalent Population of NMO/NMOSD
    • 6.8.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.8.4. Total Diagnosed Population of NMO/NMOSD
    • 6.8.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.8.6. Clinical Characterization of NMO/NMOSD
    • 6.8.7. Events of NMO/NMOSD

7. Market Drivers

8. Market Barriers

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

  • Table 1: Signs and Symptoms of Neuromyelitis Optica
  • Table 2: Brain symptoms in Neuromyelitis Optica
  • Table 3: NMOSD diagnostic criteria for adult patients
  • Table 4: Red flags: Findings atypical for NMOSD
  • Table 5: Neuroimaging characteristics of NMOSD
  • Table 6: Total Prevalent Population of NMO/NMOSD in the 7MM (2016-2027)
  • Table 7: Total Prevalent Population of NMO/NMOSD in the US (2016-2027)
  • Table 8: Gender Specific Prevalence of NMO/NMOSD in the US (2016-2027)
  • Table 9: Diagnosed Cases of Neuromyelitis Optica in the US (2016-2027)
  • Table 10: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2016-2027)
  • Table 11: Clinical Characterization of NMO/NMOSD in the US (2016-2027)
  • Table 12: Events of NMO/NMOSD in the US (2016-2027)
  • Table 13: Total Prevalent Population of NMO/NMOSD in Germany (2016-2027)
  • Table 14: Gender Specific Prevalence of NMO/NMOSD in Germany (2016-2027)
  • Table 15: Diagnosed Cases of Neuromyelitis Optica in Germany (2016-2027)
  • Table 16: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2016-2027)
  • Table 17: Clinical Characterization of NMO/NMOSD in Germany (2016-2027)
  • Table 18: Events of NMO/NMOSD in Germany (2016-2027)
  • Table 19: Total Prevalent Population of NMO/NMOSD in France (2016-2027)
  • Table 20: Gender Specific Prevalence of NMO/NMOSD in France (2016-2027)
  • Table 21: Diagnosed Cases of Neuromyelitis Optica in France (2016-2027)
  • Table 22: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2016-2027)
  • Table 23: Clinical Characterization of NMO/NMOSD in France (2016-2027)
  • Table 24: Events of NMO/NMOSD in France (2016-2027)
  • Table 25: Total Prevalent Population of NMO/NMOSD in Italy (2016-2027)
  • Table 26: Gender Specific Prevalence of NMO/NMOSD in Italy (2016-2027)
  • Table 27: Diagnosed Cases of Neuromyelitis Optica in Italy (2016-2027)
  • Table 28: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2016-2027)
  • Table 29: Clinical Characterization of NMO/NMOSD in Italy (2016-2027)
  • Table 30: Events of NMO/NMOSD in Italy (2016-2027)
  • Table 31: Total Prevalent Population of NMO/NMOSD in The UK (2016-2027)
  • Table 32: Gender Specific Prevalence of NMO/NMOSD in The UK (2016-2027)
  • Table 33: Diagnosed Cases of Neuromyelitis Optica in The UK (2016-2027)
  • Table 34: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2016-2027)
  • Table 35: Clinical Characterization of NMO/NMOSD in The UK (2016-2027)
  • Table 36: Events of NMO/NMOSD in The UK (2016-2027)
  • Table 37: Total Prevalent Population of NMO/NMOSD in Spain (2016-2027)
  • Table 38: Gender Specific Prevalence of NMO/NMOSD in Spain (2016-2027)
  • Table 39: Diagnosed Cases of Neuromyelitis Optica in Spain (2016-2027)
  • Table 40: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2016-2027)
  • Table 41: Clinical Characterization of NMO/NMOSD in Spain (2016-2027)
  • Table 42: Events of NMO/NMOSD in Spain (2016-2027)
  • Table 43: Total Prevalent Population of NMO/NMOSD in Japan (2016-2027)
  • Table 44: Gender Specific Prevalence of NMO/NMOSD in Japan (2016-2027)
  • Table 45: Diagnosed Cases of Neuromyelitis Optica in Japan (2016-2027)
  • Table 46: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2016-2027)
  • Table 47: Clinical Characterization of NMO/NMOSD in Japan (2016-2027)
  • Table 48: Events of NMO/NMOSD in Japan (2016-2027)

List of Figures

  • Figure 1: Signs and symptoms of NMO/NMOSD
  • Figure 2: Clinical features of NMO/NMOSD
  • Figure 3: Neuromyelitis Optica Pathogenesis
  • Figure 4: Total Prevalent Patient Population of NMO/NMOSD in the 7MM (2016-2027)
  • Figure 5: Total Prevalent Population of NMO/NMOSD in the US (2016-2027)
  • Figure 6: Gender Specific Prevalence of NMO/NMOSD in the US (2016-2027)
  • Figure 7: Diagnosed Cases of NMO/NMOSD in the US (2016-2027)
  • Figure 8: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2016-2027)
  • Figure 9: Clinical Characterization of NMO/NMOSD in the US (2016-2027)
  • Figure 10: Events of NMO/NMOSD in the US (2016-2027)
  • Figure 11: Total Prevalent Population of NMO/NMOSD in Germany (2016-2027)
  • Figure 12: Gender Specific Prevalence of NMO/NMOSD in Germany (2016-2027)
  • Figure 13: Diagnosed Cases of NMO/NMOSD in Germany (2016-2027)
  • Figure 14: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2016-2027)
  • Figure 15: Clinical Characterization of NMO/NMOSD in Germany (2016-2027)
  • Figure 16: Events of NMO/NMOSD in Germany (2016-2027)
  • Figure 17: Total Prevalent Population of NMO/NMOSD in France (2016-2027)
  • Figure 18: Gender Specific Prevalence of NMO/NMOSD in France (2016-2027)
  • Figure 19: Diagnosed Cases of NMO/NMOSD in France (2016-2027)
  • Figure 20: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2016-2027)
  • Figure 21: Clinical Characterization of NMO/NMOSD in France (2016-2027)
  • Figure 22: Events of NMO/NMOSD in France (2016-2027)
  • Figure 23: Total Prevalent Population of NMO/NMOSD in Italy (2016-2027)
  • Figure 24: Gender Specific Prevalence of NMO/NMOSD in Italy (2016-2027)
  • Figure 25: Diagnosed Cases of NMO/NMOSD in Italy (2016-2027)
  • Figure 26: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2016-2027)
  • Figure 27: Clinical Characterization of NMO/NMOSD in Italy (2016-2027)
  • Figure 28: Events of NMO/NMOSD in Italy (2016-2027)
  • Figure 29: Total Prevalent Population of NMO/NMOSD in The UK (2016-2027)
  • Figure 30: Gender Specific Prevalence of NMO/NMOSD in The UK (2016-2027)
  • Figure 31: Diagnosed Cases of NMO/NMOSD in The UK (2016-2027)
  • Figure 32: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2016-2027)
  • Figure 33: Clinical Characterization of NMO/NMOSD in The UK (2016-2027)
  • Figure 34: Events of NMO/NMOSD in The UK (2016-2027)
  • Figure 35: Total Prevalent Population of NMO/NMOSD in Spain (2016-2027)
  • Figure 36: Gender Specific Prevalence of NMO/NMOSD in Spain (2016-2027)
  • Figure 37: Diagnosed Cases of NMO/NMOSD in Spain (2016-2027)
  • Figure 38: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2016-2027)
  • Figure 39: Clinical Characterization of NMO/NMOSD in Spain (2016-2027)
  • Figure 40: Events of NMO/NMOSD in Spain (2016-2027)
  • Figure 41: Total Prevalent Population of NMO/NMOSD in Japan (2016-2027)
  • Figure 42: Gender Specific Prevalence of NMO/NMOSD in Japan (2016-2027)
  • Figure 43: Diagnosed Cases of NMO/NMOSD in Japan (2016-2027)
  • Figure 44: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2016-2027)
  • Figure 45: Clinical Characterization of NMO/NMOSD in Japan (2016-2027)
  • Figure 46: Events of NMO/NMOSD in Japan (2016-2027)